- $288.68bn
- $313.21bn
- $54.07bn
European shares close lower as investors weigh Middle East risks (updated)
European shares steady; Middle East tensions in focus
UK Stocks-Factors to watch on June 9 (updated)
UK Stocks-Factors to watch on June 9
Press Digest: Financial Times - June 9
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
Brief: Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial
Media: AstraZeneca chief warns group could withhold new drugs in Europe-FT
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Celcuity rises after boosted $500 mln convertible bond offering
Celcuity drops further after announcing $400 mln convertible offering
'It's still working': More are living with cancer as era of targeted drugs takes hold
Celcuity plunges after experimental breast cancer treatment data disappoints
Brief: IMFINZI Plus IMJUDO Combined With lenvatinib And TACE Reduced The Risk Of Disease Progression Or Death By 30% In Embolization-Eligible Unresectable Liver Cancer In EMERALD-3 Phase Iii Trial
Mineralys' pill cuts blood pressure in kidney disease patients
Brief: CelLBxHealth Enters Master Services Agreement With AstraZeneca
Brief: AstraZeneca Says Imfinzi Approved In US For Early Bladder Cancer
Brief: Imfinzi approved in US as first immunotherapy combo for high‑risk bladder cancer
Brief: FDA Approves Durvalumab In Combination With Bacillus Calmette-Guerin